Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Wolters Kluwer
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/2bb4b1c0048143b29f0e46696ee44349 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:2bb4b1c0048143b29f0e46696ee44349 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:2bb4b1c0048143b29f0e46696ee443492021-11-25T07:58:36ZObinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies2572-924110.1097/HS9.0000000000000664https://doaj.org/article/2bb4b1c0048143b29f0e46696ee443492021-12-01T00:00:00Zhttp://journals.lww.com/10.1097/HS9.0000000000000664https://doaj.org/toc/2572-9241Natali PflugGeothy ChakupurakalAnna-Maria FinkSandra RobrechtMarco HerlingPaula CramerUdo HoltickSebastian TheurichJohannes ScheteligKirsten FischerMatthias RitgenChristof ScheidBarbara EichhorstPeter DregerMichael HallekMichael von Bergwelt-Baildonon behalf of the German CLL Study GroupWolters KluwerarticleDiseases of the blood and blood-forming organsRC633-647.5ENHemaSphere, Vol 5, Iss 12, p e664 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Diseases of the blood and blood-forming organs RC633-647.5 |
| spellingShingle |
Diseases of the blood and blood-forming organs RC633-647.5 Natali Pflug Geothy Chakupurakal Anna-Maria Fink Sandra Robrecht Marco Herling Paula Cramer Udo Holtick Sebastian Theurich Johannes Schetelig Kirsten Fischer Matthias Ritgen Christof Scheid Barbara Eichhorst Peter Dreger Michael Hallek Michael von Bergwelt-Baildon on behalf of the German CLL Study Group Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies |
| format |
article |
| author |
Natali Pflug Geothy Chakupurakal Anna-Maria Fink Sandra Robrecht Marco Herling Paula Cramer Udo Holtick Sebastian Theurich Johannes Schetelig Kirsten Fischer Matthias Ritgen Christof Scheid Barbara Eichhorst Peter Dreger Michael Hallek Michael von Bergwelt-Baildon on behalf of the German CLL Study Group |
| author_facet |
Natali Pflug Geothy Chakupurakal Anna-Maria Fink Sandra Robrecht Marco Herling Paula Cramer Udo Holtick Sebastian Theurich Johannes Schetelig Kirsten Fischer Matthias Ritgen Christof Scheid Barbara Eichhorst Peter Dreger Michael Hallek Michael von Bergwelt-Baildon on behalf of the German CLL Study Group |
| author_sort |
Natali Pflug |
| title |
Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies |
| title_short |
Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies |
| title_full |
Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies |
| title_fullStr |
Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies |
| title_full_unstemmed |
Obinutuzumab in Allogeneic Transplantation for CLL and Richter’s Transformation in the Age of Targeted Therapies |
| title_sort |
obinutuzumab in allogeneic transplantation for cll and richter’s transformation in the age of targeted therapies |
| publisher |
Wolters Kluwer |
| publishDate |
2021 |
| url |
https://doaj.org/article/2bb4b1c0048143b29f0e46696ee44349 |
| work_keys_str_mv |
AT natalipflug obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT geothychakupurakal obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT annamariafink obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT sandrarobrecht obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT marcoherling obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT paulacramer obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT udoholtick obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT sebastiantheurich obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT johannesschetelig obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT kirstenfischer obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT matthiasritgen obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT christofscheid obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT barbaraeichhorst obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT peterdreger obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT michaelhallek obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT michaelvonbergweltbaildon obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies AT onbehalfofthegermancllstudygroup obinutuzumabinallogeneictransplantationforcllandrichterstransformationintheageoftargetedtherapies |
| _version_ |
1718413548032360448 |